在日本的mRNA COVID-19疫苗增强剂和死亡率之间的关联:金星研究
Wataru Mimura1, Chieko Ishiguro1, Megumi Maeda2
1Section of Clinical Epidemiology, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Human vaccines & immunotherapeutics
|May 17, 2024
概括
评估了COVID-19 mRNA疫苗增强剂的死亡风险. 该研究没有发现与这些增剂剂量相关的死亡风险增加,这支持了对疫苗的信心.
科学领域:
- 免疫学 免疫学 免疫学
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 之前的研究表明,在初级COVID-19 mRNA疫苗系列后,死亡风险没有增加.
- 关于COVID-19 mRNA疫苗增剂剂量对死亡率的安全性的数据有限.
研究的目的:
- 为了评估与mRNA疫苗增剂剂额相关的死亡风险,除了初级疫苗接种系列.
- 为公共卫生政策提供证据,并解决疫苗犹.
主要方法:
- 采用了一个嵌套病例控制研究设计,利用两个特定年龄的队列 (18-64岁和≥65岁).
- 确定了死亡,并根据市政,年龄和性别对每个病例进行了五次对照.
- 条件后勤回归分析估计了mRNA疫苗剂量 (1st-5th) 的调整几率比 (aORs) 与21天和42天内未接种疫苗的个人相比.
主要成果:
- 在18-64岁的队列中,在0-21天内的第三和第四剂量的aOR分别为0.62 (95%CI:0.24,1.62) 和0.38 (95%CI:0.08,1.84).
- 在≥65岁的队列中,第三,第四和第五剂量的aOR分别为0.36 (95%CI:0.31,0.43),0.30 (95%CI:0.25,0.37) 和0.26 (95%CI:0.20,0.33).
- 这些结果表明,在任何年龄组中,mRNA疫苗增剂后,死亡风险没有增加.
结论:
- mRNA COVID-19 疫苗的提升剂量与死亡风险增加无关.
- 这些发现可以为未来的疫苗接种活动提供信息,并有助于缓解疫苗犹.
- 这项研究加强了mRNA COVID-19疫苗的安全概况,包括助推剂.
相关概念视频
Bias in Epidemiological Studies
251
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
251
Confounding in Epidemiological Studies
164
Confounding in statistical epidemiology represents a pivotal challenge, referring to the distortion in the perceived relationship between an exposure and an outcome due to the presence of a third variable, known as a confounder. This variable is associated with both the exposure and the outcome but is not a direct link in their causal chain. Its presence can lead to erroneous interpretations of the exposure's effect, either exaggerating or underestimating the true association. This...
164
Vaccinations
44.4K
Overview
44.4K
Relative Risk
156
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
156
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K


